# The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

> **NCT04917770** · PHASE2 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Sintilimab in combination with Multimodality Radiotherapy

## Key facts

- **NCT ID:** NCT04917770
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-30
- **Primary completion:** 2022-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2021-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04917770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04917770, "The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04917770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*